CTI BioPharma
CTI BioPharma's Overview
CTI BioPharma Corp. was a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers and other rare diseases. Its primary product, VONJO® (pacritinib), received FDA approval for treating adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. In June 2023, CTI BioPharma was acquired by Swedish Orphan Biovitrum AB (Sobi) for $1.7 billion and now operates as a key part of Sobi's portfolio in rare disease and specialty care, particularly strengthening its hematology franchise.
Where is CTI BioPharma's Headquarters?
HQ Function
Historically, the Seattle headquarters served as the nerve center for CTI BioPharma's corporate strategy, research and development oversight, clinical trial management, and commercial preparation.
Notable Features:
The headquarters was situated in a modern office building in a key business district, offering advanced facilities conducive to a biotech firm. Specific unique architectural highlights were not a primary public feature.
Work Culture:
The work culture at CTI BioPharma, typical for a dynamic biopharmaceutical company, likely emphasized scientific innovation, patient focus, collaboration among multidisciplinary teams, and a results-oriented approach to drug development.
HQ Significance:
This headquarters was central to the successful development, FDA approval, and initial commercialization of VONJO®, representing a major milestone for the company and a new therapeutic option for myelofibrosis patients.
Values Reflected in HQ: The headquarters' operations aimed to reflect CTI BioPharma's commitment to addressing unmet medical needs in hematology and oncology, driven by scientific excellence and a patient-first mindset.
Location:
Prior to its acquisition by Sobi, CTI BioPharma maintained a strategic global presence focused on North America and Europe. Its activities encompassed multinational clinical trials, engagement with global regulatory authorities like the FDA and EMA, and building the groundwork for international commercial operations for its therapies, primarily VONJO®.
Street Address:
3101 Western Avenue, Suite 800
City:
Seattle
State/Province:
WA
Country:
USA
CTI BioPharma's Global Presence
Milan, Italy
Address: Via Mike Bongiorno 13, 20124 Milan, Italy
To support CTI BioPharma's strategic objectives in Europe, including engagement with the European Medicines Agency (EMA) and establishing a presence in key European markets for its therapeutic candidates.
Buying Intent Signals for CTI BioPharma
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of CTI BioPharma
As of April 2025, CTI BioPharma' leadership includes:
Investors of CTI BioPharma
CTI BioPharma has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
The most significant event impacting CTI BioPharma's executive team in the last 12 months was its acquisition by Sobi, completed in June 2023. This led to the transition of CTI BioPharma's leadership as the company and its operations were integrated into Sobi's global structure. Consequently, the former CTI executive team largely departed from their roles within the independent CTI entity.
Departures
New Appointments:
Technology (Tech Stack) used by CTI BioPharma
Discover the tools CTI BioPharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CTI BioPharma Email Formats and Examples
Prior to its acquisition by Sobi in June 2023, CTI BioPharma likely used standard corporate email formats such as [first_initial][last]@ctibiopharma.com. Following the acquisition, emails to the `ctibiopharma.com` domain may be inactive or redirected. For current business communications related to former CTI BioPharma assets, refer to Sobi's official contact channels.
[first_initial][last]@ctibiopharma.com
Format
jdoe@ctibiopharma.com
Example
10%
Success rate
News and media
Sobi • June 3, 2024
Sobi® presents updated overall survival data for pacritinib in patients with cytopenic myelofibrosis at ASCO 2024
Sobi announced updated results from an indirect comparison of overall survival (OS) in patients with cytopenic myelofibrosis treated with pacritinib (VONJO) versus real-world data (RWD) on best available therapy (BAT). The findings were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting....more
Sobi • June 26, 2023
Sobi® completes acquisition of CTI BioPharma Corp.
Sobi (Swedish Orphan Biovitrum AB) announced the successful completion of its recommended cash offer to acquire CTI BioPharma Corp. for $9.10 per share, representing an equity value of approximately $1.7 billion. This acquisition strengthens Sobi's position in rare hematology....more
CTI BioPharma (via PR Newswire) • February 28, 2022
CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis with Thrombocytopenia
CTI BioPharma Corp. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to VONJO (pacritinib) for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis with a platelet count below 50 × 10⁹/L....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including CTI BioPharma, are just a search away.